Log in to search using one of your social media accounts:


New therapeutic schedules of Sunitinib: Current evidence regarding the 2:1 scheme.

CONCLUSIONS: Despite the still limited amount of data, current evidence supports the use of a 2:1 schedule, as it provides patients substantial advantages because of its better tolerability profile, without a loss in oncological efficacy. Currently, the 2:1 scheme is an appropriate alternative therapeutic strategy, especially in patients with poor tolerance to the standard 4:2 regimen. PMID: 28422035 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Related Links:

As outlined in this review, adjuvant therapy for locally advanced renal cell carcinoma has remained the elusive holy grail and has been the subject of much research. Unfortunately all prior research had been negative, until recent developments again focused the spotlight on this important endeavor. Two recently completed phase III trials address the question of the role of targeted therapy with tyrosine kinase inhibitors in the adjuvant setting. The ASSURE trial, which examined the benefit of sunitinib or sorafenib vs placebo for 1 year, failed to reveal a benefit in DFS or OS (reference 39 in article).
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Review Article Source Type: research
To prospectively assess feasibility, safety, and cytoreductive effect of transarterial chemoembolization on renal cell carcinoma (RCC) using drug-eluting embolic agent (DEE) saturated with doxorubicin compared with transarterial embolization (TAE).
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Clinical Study Source Type: research
ConclusionsA past history of a malignancy elsewhere should raise the index of suspicion of metastatic disease in patients presenting with thyroid lumps with or without cervical lymphadenopathy. Detection of metastases to the thyroid generally indicates poor prognosis, obviating the need of surgery in an already compromised patient. An empirical thyroidectomy should be considered in select patients for local disease control.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
Conclusions Long-term follow-up of percutaneous renal cryoablation demonstrates low recurrence rates with preserved renal function, even for patients with high nephrometry scores and body mass index, assuming thorough cytotoxic technique and protection measures.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
AbstractBackgroundThe mortality of conventional renal cell carcinoma (RCC) correlates directly with the presence or postoperative development of metastases. The aim of this study was to identify new markers associated with the postoperative progression of conventional RCC.MethodsTissue microarrays (TMA) of conventional RCC from a cohort of 414 patients were analysed by immunohistochemistry for expression of the lipopolysaccharide binding protein (LBP), which was identified as a candidate biomarker through Affymetrix U133 Plus 2.0 array analysis. Univariate and multivariate Cox regression models were addressed to cancer-spe...
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
Abstract ObjectiveTo assess the effect of lymph node dissection (LND), number of removed nodes (NRN) and number of positive nodes (NPN) on cancer specific mortality (CSM), in contemporary vs. historical patients, with pT2‐3NanyM0 renal cell carcinoma (RCC) treated with radical nephrectomy (RN). MethodsWithin the SEER database (2001‐2013), we identified patients with non‐metastatic pT2‐3 Nany RCC who underwent RN with or without LND. Kaplan–Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used. ResultsOf 25,357 patients, 24.8% unde...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
In this study, kaempferol can significantly inhibit the invasion and migration of 786-O renal cell carcinoma (RCC) without cytotoxicity. We examined the potential mechanisms underlying its anti-invasive activities on 786-O RCC cells. Western blot was performed, and the results showed that kaempferol attenuates the manifestation of metalloproteinase-2 (MMP-2) protein and activity. The inhibitive effect of kaempferol on MMP-2 may be attributed to the downregulation of phosphorylation of Akt and focal adhesion kinase (FAK). By examining the SCID mice model, we found that kaempferol can safely inhibit the metastasis of the 786...
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research
Nivolumab, a checkpoint inhibitor directed against programmed death-1 (PD-1), was approved as the first specific immunotherapeutic agent as second-line therapy in previously treated metastatic renal cell carcinoma (RCC) patients. A 73-year-old man with metastatic RCC was treated with nivolumab. A few days after the second treatment with nivolumab, he presented with diffuse muscle pain and unilateral ptosis. ECG showed Mobitz type 2 AV block and ST —segment elevation in leads II, III, aVF, V5, and V6.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research
Authors: Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J Abstract INTRODUCTION: There are several second-line treatment options for patients with renal cell carcinoma after first-line failure of a tyrosine kinase inhibitor, especially with the recent approvals of cabozantinib, nivolumab, and the lenvatinib plus everolimus combination. A lack of reliable biomarkers and an overall lack of prospective head-to-head comparisons make it a challenge to choose a second-line treatment in the clinic. Areas covered: In this review/meta-opinion, we descri...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma | Study | Toxicology | Urology & Nephrology